Located in Cambridge,
our laboratory works at
the interface of chemistry
and biology with a focus
on protein chemistry and
targeted cancer therapeutics.
LATEST NEWS
Our new work describing small molecules that degrade genomes of SARS-CoV-2 has been
published in ACS Central Science and highlighted in several media, including Fierce Biotech. This study describes a method to convert RNA binders into degraders, which are utilised to target two RNA structures in the
genome of SARS-CoV-2. These molecular constructs are demonstrated to degrade their targets and
exert anti-SARS-CoV-2 effects in a number of model systems.
LATEST NEWS
Congratulations to Gonçalo, who has been recognised by the European Federation for Medicinal Chemistry and Chemical Biology with the EFMC-WuXi AppTec Award for Excellence in Chemical Biology.
Gonçalo's remarkable research in developing a new strategy for 'hijacking' and degrading RNA, dubbed meCLICK-Seq, is recognised in this award. Full details about the award can be found here.